Loading organizations...
§ Private Profile · Jiading, Shanghai, China
Pharmaceutical company developing RNAi therapeutics and siRNA drugs for the pharmaceutical sector, focused on RNAi therapies.
Founded in 2021, Bowang Pharmaceutical, operating commercially under the name Argo Biopharma, is a biotechnology enterprise located in Shanghai, China, that develops RNA interference drugs and small interfering RNA therapies. The organization utilizes a specialized research and development platform focused entirely on creating advanced siRNA therapies to address complex conditions for clients within the global pharmaceutical sector. By specializing exclusively in the RNAi therapeutics market, the company aims to manufacture and deliver these targeted treatments to serve the specific needs of its pharmaceutical customers. To support its ongoing business operations and scale its platform, the enterprise has successfully secured a total of $103.85 million in funding across multiple investment stages. This financial capitalization includes a $40.99 million Series A-II financing round completed approximately two years ago to further accelerate its therapeutic programs and overall corporate growth.
Bowang Pharmaceutical has raised $41.0M across 1 funding round.
Bowang Pharmaceutical has raised $41.0M in total across 1 funding round.
Bowang Pharmaceutical has raised $41.0M in total across 1 funding round.
Bowang Pharmaceutical's investors include Zhang Yi, Trinity Innovation Fund.
Bowang Pharmaceutical has raised $41.0M across 1 funding round. Most recently, it raised $41.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $41M Series A | — | Zhang YI, Trinity Innovation Fund | Announced |